Small Molecule Antagonists for Chronic Allergy Treatment
Novel Small Molecule MRGPRX2 Antagonists for the Treatment of Allergic Reactions
Tags: The University of Hong Kong, Hong Kong, Healthcare & Lifesciences
This technology introduces novel small molecule MRGPRX2 antagonists for treating allergic reactions, specifically targeting non-IgE-mediated allergies such as atopic dermatitis, psoriasis, and rosacea. These small molecules, developed using computational design, bind to MRGPRX2 to inhibit its activity, addressing the unmet need for effective treatments targeting this receptor. In vivo studies show significant reduction in epidermal thickness, mast cell degranulation, and systemic anaphylaxis symptoms compared to non-treatment groups. Applications include oral and topical formulations for chronic allergic conditions, offering precise and effective management of allergies. Protected under US application no. 17/334,872, this technology holds strong potential for advancing allergy therapeutics.
IP Type or Form Factor: Patent Pending; Material; Platform
TRL: 3 - proof of concept with needs validated
Industry or Tech Area: Pharmaceutical Engineering; Healthcare Consumer



